Journal article · 2017 · Open access
Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets?
SCRIPTed A Journal of Law Technology & Society, 14(1) · Published 20 June 2017 · DOI 10.2966/scrip.140117.81
In brief
“Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets?” is a 2017 journal article by Tsung-Ling Lee and Tamra Lysaght, published in SCRIPTed A Journal of Law Technology & Society. OpenAlex counts 4 citations as of 19 November 2026, which puts it in the top 8% of works published in 2017 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at SCRIPTed A Journal of Law Technology & Society.
- Citations
- 4
- Most cited in
- 2018 (2)
- Field-weighted impact
- 0.78
- References
- 3
- Authors
- 2
Abstract
In response to calls for faster access to innovative biomedicines, the European Medical Agency ran a two-year pilot program known as the “Adaptive Pathways” (AP) scheme. Under this approach, evidence is gathered and evaluated iteratively for license adaptation to reduce uncertainties rather than in an accumulative phased trial process. With the European Medicines Agency (EMA) aiming to mainstream the AP scheme, the regulatory approach of accelerating the approval process for novel biomedicines is in need of critical evaluation and should be viewed with some caution. Focusing on the recent market authorisation of a stem cell product, we scrutinise the legal and ethical merits of this programme. We draw attention to how the AP scheme will grant conditional marketing approval to medicinal products with limited clinical benefits. In response to the identified weaknesses of the AP scheme, we propose procedural safeguards which are in keeping with the EMA’s public health missions.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Lee, T.-L., & Lysaght, T. (2017). Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets? SCRIPTed A Journal of Law Technology & Society, 14(1). https://doi.org/10.2966/scrip.140117.81
MLA 9
Lee, Tsung-Ling, and Tamra Lysaght. “Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets?” SCRIPTed A Journal of Law Technology & Society, vol. 14, no. 1, 2017. https://doi.org/10.2966/scrip.140117.81.
Chicago
Lee, Tsung-Ling and Tamra Lysaght. 2017. “Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets?” SCRIPTed A Journal of Law Technology & Society 14 (1). https://doi.org/10.2966/scrip.140117.81.
Harvard
Lee, T.-L. and Lysaght, T. (2017) ‘Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets?’, SCRIPTed A Journal of Law Technology & Society, 14(1). doi:10.2966/scrip.140117.81.
IEEE
T.-L. Lee and T. Lysaght, “Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets?,” SCRIPTed A Journal of Law Technology & Society, vol. 14, no. 1, 2017, doi: 10.2966/scrip.140117.81.
BibTeX
@article{lee2017adaptive,
title = {{Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets?}},
author = {Lee, Tsung-Ling and Lysaght, Tamra},
journal = {SCRIPTed A Journal of Law Technology \& Society},
year = {2017},
volume = {14},
number = {1},
doi = {10.2966/scrip.140117.81},
url = {https://doi.org/10.2966/scrip.140117.81}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- adaptive pathways
- stem cell products
- conditional marketing authorisation
- drug regulation
- European Medicines Agency
- procedural guarantees
- access to medicines
Work with this paper
Most-cited papers in Nursing
- Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled StudyÖmer Toprak, Hüseyin Kurt, Yasin Sarı and 3 more · Kidney & Blood Pressure Research · 2017 · 29,772 citations
- The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm InfantsElda Dermyshi, Yizhong Wang, Chongbing Yan and 4 more · Neonatology · 2017 · 24,587 citations
- Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.Donald E. Paglia, William N. Valentine · PubMed · 1967 · 10,901 citations
- Maternal and child undernutrition and overweight in low-income and middle-income countriesRobert E. Black, Cesar Gomes Victora, Susan P. Walker and 8 more · The Lancet · 2013 · 9,505 citations
- The content validity index: Are you sure you know what's being reported? critique and recommendationsDenise F. Polit, Cheryl Tatano Beck · Research in Nursing & Health · 2006 · 8,193 citations
Questions about this paper
How do I cite this paper in APA style?
Lee, T.-L., & Lysaght, T. (2017). Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets? SCRIPTed A Journal of Law Technology & Society, 14(1). https://doi.org/10.2966/scrip.140117.81
How many times has this paper been cited?
4 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at SCRIPTed A Journal of Law Technology & Society: sign in and open the PDF from this page.
Who wrote this paper?
Tsung-Ling Lee, Tamra Lysaght.
What is the DOI of this paper?
10.2966/scrip.140117.81, permanently at https://doi.org/10.2966/scrip.140117.81. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.